

REMARKS

Claims 40-47 have been canceled without prejudice or disclaimer. Claim 48-66 have been added and therefore are pending in the present application. Claims 48-66 are supported by claims 40-47. An abstract of the disclosure has been added.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. The Rejection of Claims 40-47 under the Doctrine of Obviousness-Type Double Patenting

Claims 40-47 are rejected under the doctrine of obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent No. 5,766,898.

Applicants enclose a Terminal Disclaimer Under 37 CFR 1.321 disclaiming the terminal portion of any patent granted on the above-identified application which would extend beyond the expiration date of the above-noted US patent. Applicants, therefore, submit that this rejection has been overcome.

II. The Rejection of Claims 40-47 under 35 U.S.C. 112

Claims 40-47 are rejected under 35 U.S.C. 112 as being indefinite. Claims 40-47 have been rewritten as claims 48-66, as suggested by the Examiner. Applicants therefore submit that this rejection has been overcome.

III. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 1, 2001


Elias J. Lambiris, Reg. No. 33,728
Novozymes North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123